Editorial Disclaimer: TotalCareMedical.com is an independent health and wellness research publication. This is not a medical practice. The platforms compared in this article are operating telehealth services that connect patients with licensed clinicians for compounded GLP-1 medication evaluation. Compounded GLP-1 medications are not FDA-approved finished drugs. Nothing in this article constitutes medical advice. Pricing referenced reflects each platform's published rates as of the review date.
The compounded-GLP-1 telehealth category has compressed pricing rapidly over the past eighteen months. Three platforms occupy the value end of the market that most patients evaluate: Oak Longevity, Mochi Health, and Hims. Each markets aggressively on price. Each presents the price differently. Patients comparing them on the marketing copy alone will not arrive at the right answer for their specific situation. This comparison takes the published pricing structures, normalizes them to total monthly out-of-pocket cost, and identifies which platform actually wins on cost — and where each platform fits clinically beyond the cost question.
Headline Pricing — What Each Platform Publishes
Oak Longevity publishes compounded semaglutide from $130 per month and compounded tirzepatide from $199 per month, with no separate membership fee, free shipping, and free health coaching included. The platform offers $50 off the first month with promotional code OAKNEW50.
Mochi Health publishes a $79 per month membership fee that includes provider visits, registered dietitian access, and care coordination, plus a separate $99 per month for compounded semaglutide or $199 per month for compounded tirzepatide at every dose. Total monthly out-of-pocket cost on Mochi semaglutide is therefore $178 per month, and Mochi tirzepatide is $278 per month.
Hims publishes compounded semaglutide injectable plans starting at $199 per month with a six-month prepayment commitment (approximately $1,194 upfront), and oral kit options starting at $69 per month with a ten-month prepayment commitment (approximately $690 upfront). The headline $69 per month figure refers to non-GLP-1 oral kit combinations rather than the GLP-1 active ingredient itself; the GLP-1 injectable pricing on Hims starts at $199 per month with prepay.
Total Monthly Cost — Normalized
Comparing on a single month, no prepayment, compounded semaglutide basis: Oak Longevity at $130 is the lowest. Mochi Health at $178 total is second. Hims at $199 with a six-month prepayment commitment is third by per-month figure but requires the most upfront capital.
Comparing on annualized cost at the published starting prices, semaglutide only: Oak at approximately $1,560 per year. Mochi at approximately $2,136 per year. Hims at approximately $2,388 per year on the six-month prepay structure. The difference between Oak and Mochi over a year — roughly $576 — is meaningful for patients on long-term GLP-1 therapy.
For tirzepatide, the gap narrows. Oak Longevity from $199 per month is approximately $2,388 per year. Mochi at $79 + $199 = $278 per month is approximately $3,336 per year. The Oak-to-Mochi annual gap on tirzepatide is approximately $948 — even larger in absolute dollars, though smaller as a percentage.
One critical caveat applies across all three platforms: these are starting or flat-rate published prices. Across the compounded-GLP-1 telehealth category, dose-specific pricing varies. Patients should confirm during the consultation whether the headline price applies at every titration step, particularly as patients move from initial low doses to clinically effective maintenance doses. This is a question worth asking on every platform, not just Oak. We covered the dose-titration consideration in detail in our Oak Longevity review.
Intake and Clinical Depth
Cost is one variable. Clinical fit is another. The three platforms differ meaningfully on how the clinical relationship is structured.
Oak Longevity uses an asynchronous intake — an online health questionnaire reviewed by a licensed provider, with no scheduled video visit required for initial evaluation. This is the fastest intake of the three and works well for patients with straightforward weight-management goals and no significant comorbid complexity. Patients can typically progress from intake to prescription approval within hours.
Mochi Health emphasizes live video visits with a board-certified obesity medicine physician or nurse practitioner, plus access to a registered dietitian for nutrition coaching. Mochi's care model is the most clinically intensive of the three. The cost — $79 per month membership for what would otherwise be billed as multiple separate visits and consultations — accounts for that depth. Patients with multiple comorbidities, complex weight histories, or those who want a registered dietitian's involvement will find Mochi's structure better suited even at the higher price.
Hims operates predominantly asynchronously, similar to Oak, but with structured follow-up check-ins built into the multi-month prepayment plan. The Hims clinical experience sits within a broader men's-health ecosystem rather than a dedicated obesity medicine specialty, though its providers are licensed clinicians who prescribe within state regulations.
Formulary Breadth
Patients who want only compounded semaglutide or compounded tirzepatide will find adequate access on all three platforms. The differences emerge when other options are needed.
Mochi Health offers the broadest formulary in the category, including FDA-approved brand-name medications when clinically appropriate (Wegovy, Ozempic, Mounjaro, Zepbound, Saxenda, Trulicity, Rybelsus), oral semaglutide tablets (the FDA-approved Rybelsus pathway), and non-GLP-1 alternatives (metformin, topiramate, naltrexone, bupropion, orlistat). Mochi also operates a pediatric-eligible weight-management program for patients under 18 with appropriate clinical criteria, which neither Oak nor Hims publishes.
Hims offers brand-name medications alongside compounded semaglutide and several oral kit combinations that include non-GLP-1 active ingredients. The Hims formulary is narrower than Mochi's but broader than Oak's.
Oak Longevity's formulary is compounded-focused, primarily compounded semaglutide and compounded tirzepatide. Patients seeking FDA-approved brand-name medications, oral GLP-1 tablets, or non-GLP-1 alternatives should confirm availability with Oak directly during the intake or evaluate a platform with broader documented options. For more on what compounded versus brand-name actually means for cost and outcomes, see our Compounded Semaglutide Cost analysis.
Brand-Name FDA-Approved Access
This is where the platforms diverge most sharply. Patients who specifically want — or whose clinical situation requires — an FDA-approved brand-name GLP-1 medication should plan accordingly.
Mochi Health and Hims both offer documented pathways to FDA-approved Wegovy, Ozempic, Mounjaro, and Zepbound when clinically appropriate. Brand-name medications cost substantially more out-of-pocket — typically several hundred to over a thousand dollars per month without insurance coverage — but represent the medications studied in the peer-reviewed STEP and SURMOUNT trials.
Oak Longevity's published platform is compounded-focused. The on-domain SynergyRx review covers a platform with broader brand-name access at higher prices. We covered SynergyRx's pricing structure for brand-name medications in our SynergyRx review, where Wegovy and Mounjaro start at approximately $947 per month and Ozempic starts at approximately $499 per month.
Cancellation and Commitment
Oak Longevity advertises “no subscriptions” and bills month-to-month based on the published platform information. Patients can stop ordering refills without committing to a fixed-duration contract. This flexibility has real value for patients uncertain whether GLP-1 therapy will fit their life long-term.
Mochi Health offers monthly billing as the default, plus 3-month and 12-month prepayment options that reduce the monthly figure by roughly $40. Cancellation is straightforward but requires actively cancelling both the membership and the medication subscription separately — a structure that has produced significant complaint volume in consumer review databases.
Hims requires multi-month prepayment commitments for the headline pricing tiers. The six-month prepay for injectable semaglutide and the ten-month prepay for oral kits both involve substantial upfront capital. Patients who change their mind during the prepayment period face refund navigation.
Side Effect Support
One operational detail that does not show up in pricing comparisons: whether the platform offers prescription anti-nausea medication access. Nausea is the most common side effect of GLP-1 initiation and titration. Some platforms include ondansetron or similar prescription support when clinically appropriate; others do not.
Mochi Health publishes ondansetron access as part of the supportive care framework. Hims' broader pharmacy network includes anti-nausea options. Oak Longevity, based on Trustpilot user reports, has been noted as not currently offering prescription anti-nausea support alongside the GLP-1 prescription. Patients prone to nausea or with prior GLP-1 nausea history may want to confirm this availability with Oak directly or weight it as a factor in platform choice.
Who Each Platform Fits Best
Oak Longevity fits patients who want the lowest published starting price for compounded semaglutide on a no-membership-fee, no-prepayment basis, who are comfortable with asynchronous intake, and whose clinical situation is straightforward. The single-figure monthly price is the cleanest in the category.
Mochi Health fits patients who value live video provider access, registered dietitian involvement, broad formulary including brand-name and non-GLP-1 alternatives, and structured ongoing clinical care, and who can absorb the higher monthly total cost in exchange for that clinical depth.
Hims fits patients who can commit to multi-month prepayment, want access to both compounded and brand-name medications, and prefer the integration of weight management within a broader men's-health platform context.
The Honest Read
Oak Longevity wins the published-starting-price comparison on a no-commitment basis. That is real. It is also a starting price, and what any specific patient pays at maintenance dose depends on questions that must be answered during the consultation, not from a comparison table.
Mochi Health is more expensive monthly but delivers a more clinically intensive program with a broader formulary. For patients whose clinical situation benefits from that depth, the price differential is the right tradeoff. For patients with simpler situations, it is overpaying for unused capacity.
Hims is the highest barrier to entry due to prepayment requirements and is the most ecosystem-integrated platform of the three. Patients who already use Hims for other men's-health services may find the integration valuable; patients evaluating purely on weight-management terms will find better fit elsewhere.
For deeper coverage of the compounded GLP-1 telehealth category, see our Telehealth Platform Reviews hub. For evidence-based weight management beyond pharmaceutical interventions, see our Weight Management coverage. The clinical decision to use any GLP-1 medication, compounded or brand-name, belongs to the patient and a licensed healthcare provider.
Editorial Disclaimer: TotalCareMedical.com is an independent wellness research publication. It is not a medical practice and does not provide clinical care. All content is editorial and educational — not medical advice, diagnosis, or treatment. Compounded medications are prepared by licensed compounding pharmacies based on individual prescriptions and are not FDA-approved finished drugs. Pricing referenced reflects each platform's published rates as of the review date and is subject to change.